Know Cancer

forgot password

Medical Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

18 Years
Open (Enrolling)
Multiple Myeloma, Waldenstrom's Macroglobulinemia, Smoldering Multiple Myeloma, Lymphoblastic Lymphoma

Thank you

Trial Information

Medical Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

- Participants will be asked to complete a medical survey which includes demographics,
diagnosis, and treatment history, medical history, lab results and symptoms

- Participants will then receive instructions for the tissue banking procedure, which
involves donating bone marrow and blood samples. These will be collected only at times
when necessary clinical bone marrow samples are obtained and will not require an extra
visit to the doctor.

- The investigators are also requesting permission to collect medical information from
the participant's record and link this information to the specimens so that we may
better understand the participant's response to treatment. For samples obtained prior
to beginning therapy, this information might allow us to develop new ways of predicting
response to therapy. The investigators are also requesting permission to store samples
of blood and bone marrow to establish a tissue bank for future research to these
diseases. These samples will be de-identified; any of the participant's personal
health information identifiers will be removed.

- The tumor sample may be obtained at diagnosis, during treatment and/or as the time of
relapse. The timing of sample collection will coincide with other bone marrow tests
required to assess the response to therapy or any other clinical purpose.

Inclusion Criteria:

- Any individual diagnosed with Multiple Myeloma, Waldenstrom Macroglobulinemia, MGUS,
smoldering MM or other lymphoplasmacytic lymphomas

- Signed informed consent

- 18 years of age or older

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:


Outcome Description:

To establish a databank of patients with MM, WM, MGUS, sMM, or related disorders. This databank will include medical history data and bone marrow and peripheral blood samples.

Outcome Time Frame:

3 years

Safety Issue:


Principal Investigator

Irene Ghobrial, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute


United States: Institutional Review Board

Study ID:




Start Date:

December 2009

Completion Date:

December 2020

Related Keywords:

  • Multiple Myeloma
  • Waldenstrom's Macroglobulinemia
  • Smoldering Multiple Myeloma
  • Lymphoblastic Lymphoma
  • Waldenstrom
  • myeloma
  • smoldering
  • lymphoma
  • MGUS
  • distinct B-cell lymphoproliferative disorder
  • Lymphoma
  • Waldenstrom Macroglobulinemia
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Lymphoma, Non-Hodgkin



Dana-Farber Cancer InstituteBoston, Massachusetts  02115